Can Metabolic Regulators Fight Metastatic Melanoma?

Vemurafenib, an inhibitor of mitogen-activated protein kinase signaling downstream of BRAFV600E, can be successfully used to treat patients with metastatic melanoma. However, it produces a high incidence of therapeutic resistance. New strategies are needed to treat vemurafenib-resistant melanoma, so researchers used two bioactive compound libraries and identified two possible targets: deguelin and rotenone. "Breakthroughs in understanding the molecular basis for the disease have led to a couple ...

Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2022 Oncology Data Advisor. All rights reserved.